LILY LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss
- Coordinator
- Luminate Medical Limited, Ireland
- Runs
- 1 October 2023 to 31 March 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.1m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190130710
What the project is doing
In the project's own words, from its summary on CORDIS.
Chemotherapy-induced alopecia (CIA) is hair loss associated with chemotherapy treatment for cancer. LILY is a portable, comfortable, and effective CIA prevention device that uses localised microvasculature compression therapy (LMCT) to prevent CIA. The LILY device uses this unique LMCT technique to reduce perfusion at the scalp and prevent the destructive action of chemotherapy on hair follicles. By applying a consistent low-level pressure (between 35 and 60 mmHg) to the local micro blood vessels, which could deliver chemotherapy drugs to fast-dividing hair follicles, the vessels are temporarily compressed, inhibiting drug delivery.
The device comprises a proprietary pneumatic bladder network design and soft robotics system with the ability to non-invasively induce vasoconstriction in superficial vessels of the scalp to mechanically control tissue perfusion, and an electronic control system for both patient management of the system and real-time feedback into the treatment protocol.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Luminate Medical Limited | Galway | Ireland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI